Showing results (111-120 of 326) with videos related to
Sort By:
Pageof 33
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2020
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based RegimensJai N Patel, Myra Robinson, Megan Jagosky, et al.Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.Journal of Athletic Training|December 19, 2018
Cooling Rates of Hyperthermic Humans Wearing American Football Uniforms When Cold-Water Immersion Is DelayedKevin C Miller, Timothy A Di Mango, Grace E KattJournal of Athletic Training|March 1, 2022
Body Anthropometric Characteristics and Rectal Temperature Cooling Rates in Women With HyperthermiaFallon S Koenig, Kevin C Miller, Paul O'Connor, et al.Clinical Case Reports|April 4, 2015
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocolsZeba N Singh, Yogesh Jethava, Ginell R Post, et al.Oncology and Therapy|June 4, 2023
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple MyelomaStephen Palmer, Yi Lin, Thomas G Martin, et al.Transplantation and Cellular Therapy|September 3, 2023
Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable DiscussionQaiser Bashir, Marc Braunstein, Tondre Buck, et al.Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Evaluation of Montelukast for the Prevention of Infusion-related Reactions With DaratumumabDonald C Moore, Justin R Arnall, Daniel L Thompson, et al.Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.Expert Review of Pharmacoeconomics & Outcomes Research|February 24, 2026
Comparative cost per responder analysis of Ciltacabtagene autoleucel and real-world standard of Care therapy in patients with lenalidomide-refractory multiple myelomaDoris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, et al.Pageof 33